Health ❯ Healthcare ❯ Clinical Trials

Drug Development

Combination Therapy Phase 3 Trials Eli Lilly Targeted Therapy Phase III Trials Oncology Alzheimer's Treatments RAS Inhibitors Daraxonrasib Patient Outcomes

Erasca Prices $550 Million Upsized Share Sale as Early ERAS-0015 Data Draw Attention

The company says proceeds will fund research and trials to move ERAS-0015 toward planned combination plus expansion readouts in 2027.

FDA Clears Wearable Injector Form of Sanofi’s Multiple Myeloma Drug

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Moderna Repositions as Broad mRNA Company After Investor Day Rally

Study Maps How Leukemia Enters Lungs and Identifies Drug Targets

Biogen to Buy RayThera for Up to $1 Billion

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

U.S. Biotech Reports Major Survival Gain in Pancreatic Cancer as Hiroshima Plans 2028 Trial for MicroRNA Mesothelioma Drug

Abivax Drug Shows Breakthrough Ulcerative Colitis Results as Shares Plunge After Cancer Cases

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

Experimental ERAP1 Inhibitor Plus Immunotherapy Shrinks Tumours in Early Trial

Praxis Drug Vormatrigine Misses Primary Goal in Phase 2/3 POWER1 Trial

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Amivantamab Injection Eradicates Tumours in Treatment‑Resistant Head and Neck Cancer Trial

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

Mezigdomide Triplet Cuts Risk of Myeloma Progression by 52% in Phase 3 Trial

NEJM Paper Shows Zanidatamab Triplet Extends Survival Over Trastuzumab in First‑Line HER2+ Gastroesophageal Cancer